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Zeta-associated protein (ZAP)-70 is a cytoplasmic protein tyrosine kinase required for T  cell 
antigen  receptor  (TCR)  signaling  and  development. Mutations  in  ZAP-70  result  in  severe 
combined immunodeficiency in humans.  ZAP-70 interacts with the TCR by binding to ty- 
rosine-phosphorylated immunoreceptor tyrosine-based activation motifs  (ITAMs)  present in 
the invariant subunits of the TCR complex. Here we report that two ZAP-70 mutants devoid 
of kinase activity, generated either by a point mutation in the kinase domain to create an inac- 
tive kinase,  or by truncation of the entire kinase domain (SH2[N+C]),  functioned as domi- 
nant-negative mutants to specifically suppress  TCR-mediated activation of NFAT,  a nuclear 
factor  essential  for  inducible  interleukin  2  gene  expression.  Biochemical  studies  with  the 
SH2(N+C) mutant showed that it also blocked early TCR signaling events, such as p95  vav ty- 
rosine phosphorylation, extracellular signal-regulated kinase 2 activation, and the association of 
a number of tyrosine-phosphorylated proteins with growth factor receptor-binding protein 2 
(GRB2). The inhibitory effects of the SH2(N+C)  mutant revealed that it requires an intact 
phosphotyrosine-binding site in its COOH-terminal SH2 domain. Using a CD8-~  chimeric 
receptor to  analyze the  interaction of the  SH2(N+C)  mutant with  ITANIs of TCR-~,  we 
found that this mutant was constitutively bound to the hyperphosphorylated CD8-~ chimera. 
These results  indicate that tyrosine-phosphorylated ITAM is the target for the action of this 
dominant-negative  mutant,  suggesting  that  the  assembly  of a  functional  receptor signaling 
complex on ITAMs is a critical proximal TCR signaling event leading to downstream activation. 
T 
he  TCR  is  a  multimolecular  complex consisting  of 
clonotypic  antigen-binding subunits (or and 13 in most 
T  cells) and invariant signal-transducing subunits (% B, and 
e  chains of the CD3  complex, and ~ family proteins)  (1). 
Engagement of the TCR by antigen bound to MHC mol- 
ecules or by anti-TCR mAbs triggers a signal  transduction 
cascade culminating in the induction of a variety of T  cell 
functions (1). One of the earliest detectable signaling events 
after TCR stimulation is the tyrosine phosphorylation of a 
number of protein substrates,  including the invariant sub- 
units  of the  TCR  complex,  phospholipase  C  (PLC)I~/1, 
p95  ray, zeta-associated protein (ZAP)-70, Shc, and valosin- 
containing  protein  (VCP)  (1).  However,  unlike  many 
growth  factor receptors, the  TCR  lacks  intrinsic  protein 
tyrosine kinase (PTK) activity. Numerous biochemical and 
1Abbreviations used in this paper: ERK2, extraceUular  signal-regulated  kinase 
2; GRB2, growth factor  receptor-binding  protein 2; HM1, human mus- 
carinic subtype 1 receptor;  ITAM, immunoreceptor  tyrosine-based  acti- 
vation motifi KI, inactive kinase; NFAT, nuclear factor of activated T 
cells; PLC, phospholipase  C; PTK, protein tyrosine  kinase; TAg, large T 
antigen; ZAP-70, zeta-associated  protein  70. 
genetic studies  have  shown  that  the  TCR  initiates  signal 
transduction  by  interacting  with  and  activating  at  least 
three cytoplasmic PTKs, Lck, Fyn, and ZAP-70 (1-3). Lck 
and Fyn, two members of the Src family PTK, have been 
suggested  to  initially  tyrosine  phosphorylate  the  immu- 
noreceptor tyrosine-based activation motifs (ITAMs)  con- 
tained  within  the  cytoplasmic  domains  of the  invariant 
TCR subunits.  This phosphorylation leads  to the recruit- 
ment of the Syk family PTK, ZAP-70, to the TCR (4-6). 
The association of ZAP-70 with the TCR is mediated by a 
high  affinity  interaction  between  the  two  tandemly  ar- 
ranged SH2 domains of the ZAP-70 molecule and the two 
phosphorylated tyrosines in the ITAM (5, 7-9). Both SH2 
domains of ZAP-70  are required for this association. Ty- 
rosine phosphorylation of ZAP-70 itself also takes place af- 
ter its binding to the TCR, a process dependent on the Src 
family  PTKs  (5,  8,  10).  The  functional  significance  of 
ZAP-70 tyrosine phosphorylation is still not clear, but may 
relate to its  catalytic activation and interaction with other 
proteins (11,  12). The combined activation of  both Src and 
Syk family PTKs results in tyrosine phosphorylation of cel- 
lular substrates,  which in turn contributes to the activation 
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tabolism, elevation of cytoplasmic free calcium,  P,  as-GTP 
accumulation,  and  an  extracellular signal-regulated kinase 
cascade involving several cytoplasmic serine/threonine ki- 
nases (1-3). These signaling events ultimately lead to T  cell 
differentiation, proliferation, and induction of effector func- 
tions. The requisite role of ZAP-70 in TCR  signaling has 
been  established by recent studies  (13-16)  on  human  pa- 
tients with an immunodeficiency disease caused by loss-of- 
function  mutations  of ZAP-70.  CD4 +  T  cells from  these 
patients are defective in both early and late signaling through 
the TCR.  Moreover,  these patients do not have  CD8 + T 
cells because of a developmental arrest. These findings pro- 
vide strong genetic evidence that ZAP-70 is a critical mol- 
ecule involved in T  cell signahng and development. 
Although null mutations in patients or animals can pro- 
vide insights into the importance of molecules involved in 
signal  transduction,  the  resultant  phenotype  is  a  conse- 
quence of a complex developmental program and adaptive 
mechanisms  so  that  the  precise  function  of the  affected 
molecules is often obscured. The use of dominant-negative 
mutations  in  signaling  molecules  is  an  alternatitive  ap- 
proach to investigate signal transduction pathways. In fact, 
dominant-negative  mutants  of Src  family PTKs  (Lck  and 
Fyn), Ser/Thr kinases (MAP kinase or ERK kinase [MEK] 
and Rat'), and the small GTP-binding protein t<as, have all 
been successfully used to  dissect T  cell signaling pathways 
in T  cell lines or in transgenic mice (17-24).  In this report, 
we  show  that  two  ZAP-70  mutants  can  specifically sup- 
press  TCR-mediated  early  and  late  sigalal  transduction 
leading to nuclear factor of activated T  cells (NFAT)  acti- 
vation inJurkat T  cells. 
Materials  and Methods 
Cells.  Large T  antigen  (TAg) Jurkat  cells,  described previ- 
ously (25),  are human leukemia Jurkat T  cells stably transfected 
with SV40 TAg (kindly provided by Dr.  G. Crabtree, Stanford 
University, Palo Alto, CA). J.HM1.2.2 cells have been described 
previously (26). Cells were maintained as described (25, 26). 
Plasmids.  The NFAT-luciferase reporter construct, in which 
the expression of luciferase is driven by multiple copies of NFAT 
DNA  binding element,  was  a  gift from  Dr.  G.  Crabtree.  The 
gys  369  to  Ala point mutant  (inactive kinase  [K1]) of ZAP-70, 
described previously (8),  was  subcloned into pBJl, a mamma- 
lian expression vector containing the  SRo~ promoter (27).  The 
SH2(N+C)  mutant  was  generated  by  digesting the  wild-type 
ZAP-70  cDNA  with  HindlI  at  nucleotide  position  1039  and 
then adding a stop codon next to this HindlI site. The resulting 
cDNA fragment, which encodes the amino acids 1-276 of ZAP- 
70,  was also  subcloned into  pBJ1.  The  SH2(N+*C)  was  con- 
stmcted  by  replacing the  Kpnl  (nucleotide position  701)-ScaI 
(nucleotide position 870) fragment of the SH2(N+C)  mutant in 
the pBJ1  vector with the same fragment in the full-length ZAP- 
70 containing the point mutation Arg  19~ to Lys which has been 
previously described (8). CDS-~, described earlier (28), was sub- 
cloned into pEF-BOS (29). Myc epitope-tagged p95  ~v and extra- 
cellular signal-regulated kinase 2  (ER.K2)  have  been  described 
previously (30,  31)  and were subcloned into pEF-BOS.  FLAG 
epitope-tagged growth factor receptor-binding protein 2 (GR.B2), 
subcloned into pEF-BOS, was kindly provided by D. Motto and 
Dr. G. Koretzky (University of Iowa, Iowa City, IA). All expres- 
sion plasmids contain an SV40 origin of replication to allow high 
level gene expression in TAgJurkat cells (25). 
Antibodies.  The following mAbs (and their specificity) were 
used:  C305  (mouse  anti-Jurkat Ti  [3  chain)  (32),  9E10  (mouse 
anti-Myc epitope) (kindly provided by J. M.  Bishop, University 
of California, San  Francisco) (33),  4G10  (mouse antiphosphoty- 
rosine)  (purchased  from  Upstate  Biotechnology,  Inc.,  Lake 
Placid, NY),  OKT8  (mouse  anti-human  CD8)  (obtained from 
American  Type  Culture  Collection,  R.ockville,  MD),  2F3.2 
(mouse  anti-human  ZAP-70)  (8),  6Bl0.2  (mouse  anti-TCR~ 
chain) (34),  and M2 (mouse anti-FLAG epitope) (obtained from 
Eastman  Kodak  Co.,  New  Haven,  CT).  The  rabbit polyclonal 
anti-GRB2 serum was purchased from  Santa  Cruz Biotechnol- 
ogy, Inc. (Santa Cruz, CA). 
Transfections, Stimulations, Lucferase Assay,  and Solubilization.fi~r 
Biochemical Analysis.  Cells (107) were  transiently transfected by 
electroporation  using  the  Gene  Pulser  (Bio-Rad  Laboratories, 
Hercules, CA) as previously described (25). 40 h later, transfected 
cells  were  aliquoted into  a  U-bottom  96-well plate  (10S/well) 
and cultured with various stinmli (1:500  dilution ofC305 ascites, 
500  IxM carbachol, or 50 ng/ml PMA plus 1.0 txM ionomycin) 
in P,  PMI  1640  medium supplemented with  10% FCS in a final 
volume of 90  Ixl. After a  6-h stinmlation period at 37~  cells 
were  lysed in  a buffer containing  1%  Triton  X-100,  100  mM 
KPO4, pH 7.8,  and 1.0 mM dithiothreitol. Lysates (0.1 ml) were 
mixed with 0.1 ml assay buffer (200 mM KPO  4, pH 7.8,  10 mM 
ATP, 20 mM MgC12) and 0.1 ml 1.0 mM luciferin; luciferase  ac- 
tivity was measured in the MONOLIGHT  2001  Luminometer 
(Analytical Luminescence Laboratory, Inc., San Diego, CA). For 
biochemical analysis,  transfected cells were resuspended in  PBS, 
equilibrated at 37~  for 15 min, stinmlated at 37~  with a 1:50(I 
dilution ofC305 ascites, 50 ng/ml PMA, or a 1:1,000  dilution of 
OKT8 ascites for 2 min, and lysed immediately in a buffer con- 
taining 1% NP-40,  10 mM Tris, pH 7.6,  15(1 mM NaCI, 2 mM 
EDTA,  protease,  and  phosphatase inhibitors, as  previously de- 
scribed (35). 
Immunoprecipitation and Immunoblot Analysis.  Inmmnoprecipi- 
tation was carried out as described earlier (36). Immunoblot anal- 
ysis using the  commercial  enhanced  chelmluminescence  (ECI.) 
(Amersham Corp., Arlington Heights, I1) detection kit was  per- 
formed  as  previously  described  (37).  Stripping  and  reprobing 
blots was carried out according to the ECL kit instruction pro- 
vided by Amersham Corp. P,  eprobed blots were developed using 
5-bromo-4-chloro-3-indolyl  phosphate/nitroblue tetrazolium col- 
orimetric development reagents as described (36). 
Results 
Expression  of Mutant  ZAP-70 Lacking Kinase Activity  In- 
hibited TCR-mediated NFATActivation.  We used two  mu- 
tants of ZAP-70 to examine the ability of inactive forms of 
ZAP-70 to inhibit TCR  signaling (Fig. 1). The KI mutant 
has  a  point  mutation  in  the  ATP-binding  site  (Lys  36'~ to 
Ala) of the kinase domain that results in an inactive kinase 
(8). The SH2(N+C)  mutant is a kinase domain truncation 
mutant (deletion of the COOH-terminal 343 amino acids), 
which leaves only the two SH2 domains of ZAP-70.  As a 
means  to  assess  functional T  cell activation, the  transcrip- 
tional activity of NFAT, a well-characterized nuclear factor 
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Figure 1.  Schematic  representation of  mutant ZAP-70 constructs. 
that facilitates  the  transcription  of the  IL-2 gene  (38),  was 
measured.  The induction of NFAT has been shown to be 
responsive  to  TCR-mediated  signaling  (38-40).  Plasmids 
contaitfing different ZAP-70 mutant cDNAs and the NFAT- 
luciferase reporter were cotransfected into TAgJurkat cells, 
and  luciferase  activity  was  measured  after  treatment  with 
different stimuli.  Stimulation with an anti-TCR mAb C305 
resulted  in a greater than  10-fold increase in the luciferase 
activity in control cells  cotransfected with the empty vector 
(Fig. 2 A). However, this TCR-stimulated luciferase activ- 
ity  was  markedly  inhibited  by  cotransfection  of a  cDNA 
construct  encoding either  the  KI  or the  SH2(N+C)  mu- 
tant  (Fig.  2  A).  The  inhibitory effect of either mutant  on 
NFAT-luciferase induction appeared to be dose dependent 
(Fig. 3).  Expression of the KI mutant also inhibited  TCR- 
mediated  transcriptional  activation  of NF-IL2A  (data  not 
shown),  another  nuclear factor involved in  IL-2 gene  ex- 
pression  (38).  However,  expression  of the  KI mutant  had 
little or no effect on the constitutive activation of  a reporter 
construct containing the RSV promoter (data not shown), 
suggesting that  the  KI  mutant  did  not randomly suppress 
transcription.  Moreover, cotransfection of wild-type ZAP- 
70  failed  to  inhibit  NFAT  activation  (data  not  shown). 
Cotransfection  of the  SH2(N+*C)  mutant,  in  which  the 
Arg  190  of the  FLVRs  sequence  in  the  phosphotyrosine- 
binding pocket in the  COOH-terminal  SH2  domain  was 
mutated to Lys (Fig.  1),  abolishing its ability to bind to an 
ITAM, did not inhibit anti-TCR-mediated NFAT induc- 
tion  (Fig.  2  A),  despite  similar levels  of expression  as  the 
SH2(N+C)  mutant  (Fig.  2  C).  Taken  together,  these  re- 
sults  demonstrate  that two  ZAP-70 mutants  devoid of ld- 
nase  activity  functioned  as  dominant-negative  mutants  to 
suppress TCR-mediated signaling leading to NFAT activa- 
tion.  Moreover,  the  inhibitory  effect  of the  SH2(N+C) 
mutant  requires  an  intact  phosphotyrosine-binding  site  in 
its COOH-terminal SH2 domain. 
Dominant-negative  ZAP-70  Acts  Proximally  in  the  TCR 
Signaling  Pathway  and  Is  Specific to  TCR-mediated  Signal- 
ing.  The  induction  of NFAT represents  a  late  activation 
event that is a summation of both proximal and distal TCR 
signaling.  To  investigate  the  specificity  of the  effect  of 
dominant-negative ZAP-70 mutants and whether they op- 
erate at a step(s) proximally or distally in the TCR  signaling 
pathway leading to NFAT activation, two different types of 
experiments  were performed.  In the  first  series  of experi- 
ments,  we cotransfected plasmids  containing ZAP-70 mu- 
tant  cDNA  and  the  NFAT-luciferase  reporter  into  TAg 
Jurkat  cells.  We  then  assayed luciferase  activity after treat- 
ment  with  PMA plus  ionomycin,  pharmacological  agents 
that can bypass proximal TCR signaling to activate the IL-2 
gene through the activation of protein kinase C  (PKC) and 
the  increase  of cytoplasmic  free  calcium,  respectively.  In 
the second group of experiments, we employed J.HM1.2.2 
cell,  a Jurkat  T  cell that had been stably transfected with a 
heterologous  receptor,  the  seven-transmembrane  domain 
human  muscarinic  subtype  1  receptor  (HM1).  HM1  is 
known to activate PLC[3 through a heterotrimeric  G-pro- 
Figure 2.  Effects  of different ZAP-70 mutants on NFAT activation in TAgJurkat T cells. TAgJurkat cells were cotransfected  with NFAT-luciferase 
reporter (20 Dg) together with 40 p~g of empty expression vector or expression plasmids containing cDNAs encoding different ZAP-70 mutants. 40 h 
later, transfected cells were stimulated with: (A) culture medium, anti-TCR mAb C305, or (B) PMA plus ionomycin. 6 h after stimulation, cells were 
lysed, and luciferase activity was determined. Luciferase  activity produced in cells transfected with mutant ZAP-70 expression vectors was divided by the 
activity produced in the presence of the empty expression vector. Results represent the averages of  five independent experiments. An aliquot of  cells was 
analyzed for the expression of  the SH2(N + C) (lane I) and SH2(N +*C) (lane 2) mutant proteins by immunoblotting using an anti-ZAP-70 mAb (C). 
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Figure  3.  The  inhibitory effect of KI  and 
SH2(N+C) nmtants on TCR-mediated NFAT 
activation  in TAgJurkat cells is dose dependent. 
TAg Jurkat cells were cotransfected with indi- 
cated amounts ofKI (A) or SH2(N+C) (/3) ex- 
pression  vector together with the  NFAT- 
luciferase reporter  (20  txg). The  amount  of 
DNA was adjusted to 60 ~g with the empty ex- 
pression vector. 40 h later, transfected cells were 
stimulated with culture medium or anti-TCR 
mAb C305. Relative luciferase  activity  was de- 
termined as described in Fig. 2. Results are rep- 
resentative of two separate experiments. 
tein-coupled mechanism  (41).  Stimulation of either  the 
TCR  or HM1  on J.HM1.2.2  cells leads to  IL-2 gene ex- 
pression  (41).  Mutant  ZAP-70  and  the  NFAT-luciferase 
reporter were  cotransfected into J.HM1.2.2  cells  and  the 
luciferase activity was measured after stimulation with anti- 
TCR  mAb C305  or carbachol, an agonist for HM1.  It is 
interesting to note that in contrast to their effects on NFAT 
activation induced by TCR  stimulation (Figs.  2  A  and 4 
A),  coexpression of either the KI or the SH2(N+C)  mu- 
tant failed to  inhibit NFAT activation induced by  PMA 
plus ionomycin treatment in TAg Jurkat cells (Fig. 2/3) or 
by  carbachol  stimulation in J.HM1.2.2  cells  (Fig.  4  /3). 
These results strongly suggest that both dominant-negative 
ZAP-70 mutants acted  proximally in the  TCR  signaling 
pathway, upstream of PLC activation, and that their domi- 
nant-negative effect is  specific to  the  TCR-mediated sig- 
naling pathway. 
The  biological  properties  of  both  dominant-negative 
ZAP-70 mutants appear  to  be  similar. Therefore,  we  fo- 
cused our attention on one of the dominant-negative mu- 
tants, the SH2(N+C) mutant, which also has a smaller mo- 
lecular  mass,  hence  allowing  us  to  distinguish  it  from 
endogenous ZAP-70 on  SDS-PAGE.  The  remaining ex- 
periments described in this report were performed with the 
SH2(N+C) mutant. 
Expression of the SH2(N +C) Mutant Inhibited TCR-stimu- 
latecl p95  wv  Tyrosine Phosphorylation, ERK2  Activation,  and 
the Association of a Number of Tyrosine-phosphorylated Proteins 
with GRB2.  To provide direct biochemical evidence that 
the dominant-negative ZAP-70 blocks early TCR  signal- 
ing,  we  examined three  early TCR  signaling events,  ty- 
rosine phosphorylation of p95  v~v, the activation of ERK2, 
and the association of a number of tyrosine-phosphorylated 
proteins with GRB2. p95  v"v is one of the major substrates 
of PTK activity after TCR  stimulation (42,  43).  The  in- 
volvement of p95 ~v in TCR signaling has been implicated 
by recent "knockout" and overexpression studies (30, 44- 
46).  To  assess the  effect  of expression of the  SH2(N+C) 
mutant  on  p95  w~  tyrosine  phosphorylation,  we  cotrans- 
fected  the  SH2(N+C)  mutant and a  Myc  epitope-tagged 
p95  ~av  into  TAg Jurkat  cells.  The  transfected  cells  were 
stimulated with the anti-TCR mAb C305 and the epitope- 
tagged p95  va~ was  isolated by anti-Myc epitope immuno- 
precipitation  and  analyzed  by  immunoblotting with  the 
phosphotyrosine-specific mAb,  4G10  (Fig.  5).  Expression 
of the  SH2(N+C)  mutant greatly inhibited TCR-stimu- 
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Figure  4.  Effects of different ZAP-70 mutants on 
NFAT activation in J.HM1.2.2 cells. J.HM1.2.2 cells 
were cotransfected with the NFAT-luciferase  reporter 
(20 Ixg) together with 40/*g of empty expression  vec- 
tor or expression plasmids containing  cDNAs encoding 
different ZAP-70 mutants. 40 h later, transfected cells 
were stimulated for 6 h  with: (A)  culture medium, 
anti-TCR  mAb C305, or (B) carbachol. Relative lu- 
ciferase activity was determined as described in Fig. 2. 
Results are the averages of two separate experiments. 
614  ZAP-70 in TCR Signaling Figure 5.  Expression  of  the SH2(N+C)  mutant in TAgJurkat cells in- 
hibits TCR-mediated  p95  v~v tyrosine phosphorylation. TAg Jurkat cells 
were cotransfected with 5 Ixg of Myc epitope-tagged p95  v~'v expression 
vector together with 40 Ixg of empty expression vector or expression plas- 
raids containing cDNAs encoding different ZAP-70 mutants. 40 h later, 
transfected cells were either left unstimulated or stimulated for 2 rain with 
anti-TCR mAb C305. Cells were then lysed, and Myc epitope-tagged 
p95  ray was isolated by immunoprecipitation with the anti-Myc epitope 
mAb 9E10, followed by imumnoblotting with the phosphotyrosine-spe- 
cific mAb 4Gl0  (top). The  blot was then stripped and reprobed with 
9E 10 (bottom). 
lated  tyrosine  phosphorylation  of epitope-tagged  p95  vav. 
Consistent  with  its  lack  of inhibitory  effect  on  NFAT 
induction,  the  SH2(N+*C)  mutant  did  not  block  p95  wv 
tyrosine phosphorylation.  The expression  of Myc epitope- 
tagged p95  vav was not significantly different in all the trans- 
fectants,  as determined by stripping and reprobing the blot 
with the anti-Myc epitope mAb. 
The  activation  of ERK2  is  known  to  be  another  early 
TCR  signaling event (47). Although both anti-TCR mAb 
and  the  PKC  activator PMA  stimulate  rapid  activation  of 
ERK2 in T  cells,  they appear to activate ERK2 via differ- 
ent mechanisms  (22).  To  examine the  effect of expression 
of the SH2(N+C)  mutant on the activation of ERK2, we 
cotransfected  the  SH2(N+C)  mutant  with  Myc  epitope- 
tagged ERK2  into  TAg Jurkat  cells  and  stinmlated  trans- 
fected  cells  with  either  anti-TCR  mAb  C305  or  PMA. 
Cellular lysates were then subjected to immunoblot analysis 
using the  antiepitope  mAb 9E10.  Results  shown in  Fig.  6 
indicate  that  expression  of the  SH2(N+C)  mutant  mark- 
edly inhibited the TCR-stimulated mobility shift of  ERK2, 
a commonly used marker for ERK2 activation (48).  How- 
ever,  such  inhibition  was  not  apparent  with  the  mobility 
shift of ERK2 induced by PMA stimulation,  suggesting that 
the  inhibition  is  specific  to  the  TCR-mediated  signaling 
pathway.  Correlating  with  the  failure  of the  SH2(N+*C) 
mutant to antagonize NFAT induction and p95  ~~" tyrosine 
phosphorylation,  this  mutant  also  failed  to  inhibit  TCR- 
mediated ERK2 activation. 
One well-documented early TCR  signaling event is the 
association  of a  number  of tyrosine-phosphorylated  pro- 
teins,  including pp36-38,  pp76,  and  pp116-120,  with  the 
adaptor  protein  GRB2  (49-51).  pp36-38  and  pp76  also 
associate with  PLCyl  (51,  52), whereas pp120  also associ- 
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Figure 6.  Expression  of the SH2(N+C)  mutant in TAgJurkat cells in- 
hibits TCR-mediated  ERK2  kinase activation. TAg Jurkat cells were 
cotransfected with 5 btg of Myc epitope-tagged ERK2 expression vector 
together with 40 Ixg of empty expression vector or expression plasmids 
containing cDNAs encoding different ZAP-70 mutants. 40 h later, trans- 
fected cells were left unstimulated (-), or stimulated for 2 nun with anti- 
TCR mAb C305 (+) or PMA (P). Cells were then lysed, and the whole 
cell lysates were analyzed  by immunoblotting with the anti-Myc epitope 
mAb 9El0. 
ates with PI 3-kinase (53). Thus, these tyrosine-phosphory- 
lated proteins have been proposed to have important  roles 
in linking TCR-regulated PTKs to Ras signaling, PLC ac- 
tivation,  and other signaling pathways  (49-53).  To  exam- 
ine  the  effect of expression  of the  SH2(N+C)  mutant  on 
the  association  of tyrosine-phosphorylated  proteins  with 
GRB2,  we  cotransfected  the  SH2(N+C)  mutant  with  a 
FLAG  epitope-tagged  GRB2  into  TAg Jurkat  cells  and 
stimulated transfected cells with the anti-TCR mAb C305. 
Epitope-tagged  GRB2  was  subsequently  isolated  by anti- 
FLAG epitope immunoprecipitation,  and the immunopre- 
cipitates  were  analyzed by  immunoblotting  with  the  an- 
tiphosphotyrosine  mAb  4G10  (Fig.  7)  or  an  anti-GRB2 
antibody  (data  not  shown).  Consistent  with  previous  re- 
ports, TCR  activation resulted in the appearance of several 
tyrosine-phosphorylated proteins, including pp36-38, pp76, 
and pp116-120,  that were coimmunoprecipitated with the 
antiepitope  mAb  in  control  cells  cotransfected  with  the 
empty  vector.  However,  the  recovery  of these  tyrosine- 
phosphorylated  proteins  by  anti-FLAG-GRB2  imnmno- 
precipitation  in  TCR-stimulated  cells  cotransfected  with 
the  SH2(N+C)  mutant  was  greatly  reduced.  Anti-GRB2 
imnmnoblotting showed that the amount of FLAG-GRB2 
in  all  the  immunoprecipitates  was  similar.  Since  the  asso- 
ciation  of pp36-38  with  GRB2  was  demonstrated  to  be 
mediated by the SI-t2 domain of GRB2  (51),  these  results 
strongly suggest that expression  of the  SH2(N+C)  nmtant 
inhibited the tyrosine phosphorylation ofpp36-38. The as- 
sociation of pp76 and pp 116-120 with GRB2 is not medi- 
ated by the SH2 domain but by the SH3 domain of GRB2 
(49,  50,  52).  Therefore,  a  reduction  in  the  level  of pp76 
and  pp116-120  in  anti-FLAG-GRA32 immunoprecipitates 
could be a result of inhibition  in tyrosine phosphorylation 
and/or  association  with  GRB2  by  the  expression  of the 
SH2(N+C)  mutant. 
Together,  these  results  provide  direct  biochemical  evi- 
dence that the  SH2(N+C)  mutant blocked,  at least  some, 
early TCR  signaling events. 
Association  of the SH2(N+C)  Mutant  with a  CD8-~ Chi- 
mera.  The  SH2(N+C)  mutant  requires  an  intact  phos- Figure 7.  Expression of the SH2(N+C) mutant in TAgJurkat cells in- 
hibits  TCR-stimulated  association of several tyrosine-phosphorylated 
proteins with GRB2.  TAg Jurkat cells were cotranss  with 5 Ixg of 
FLAG epitope-tagged GPd32 expression vector together with 40 Ixg of 
empty  expression vector  or the  SH2(N+C)  expression plasmid. 40  h 
later, transfected cells were  either left unstimulated or stimulated for 2 
rain  with  anti-TCR  mAb  C305. Cells were  then  lysed, and  FLAG 
epitope-tagged  GRB2  was  isolated by  immunoprecipitation  with  the 
anti-FLAG epitope mAb, followed by immunoblotting with  the phos- 
photyrosine-specific mAb 4GI0. 
photyrosine-binding site in  its  COOH-terminal  SH2  do- 
main to demonstrate its dominant-negative activity (Figs. 2 
A, 4  A,  5,  and 6),  suggesting that this mutant mediates its 
effect by binding to tyrosine-phosphorylated proteins, most 
likely tyrosine-phosphorylated TCR  subunits.  To  test  di- 
rectly  if the  SH2(N+C)  mutant  binds  to  tyrosine-phos- 
phorylated TCR  subunits, we employed a surrogate TCR, 
the  CD8-~  chimera,  in  the  transient  cotransfection  assay. 
Stimulation of this chimeric receptor with anti-CD8 mAb 
has  been  shown  to  recapitulate both  proximal  and  distal 
events  normally  associated  with  stimulation  of the  intact 
TCR  (28).  CD8-~ was cotransfected into TAg Jurkat cells 
with  either the  empty vector or the  SH2(N+C)  mutant, 
and transfected cells were unstimulated or were stimulated 
with an anti-CD8 mAb,  OKT8.  The  CD8-~  chimera was 
subsequently isolated by immunoprecipitation with OKT8 
mAb  and  analyzed by imrnunoblotting  with  anti-E,  anti- 
phosphotyrosine,  or  anti-ZAP-70  mAb.  Results  from  a 
representative experiment are shown  in Fig. 8.  Consistent 
with previous studies, anti-CD8 stimulation resulted in en- 
hanced association of endogenous ZAP-70 with CD8-~ in 
cells cotransfected with the  empty vector.  This association 
correlates with increased tyrosine phosphorylation of CD8-~. 
It is striking that expression of the SH2(N+C)  mutant re- 
suited  in  a  substantial  increase  in  the  basal level  tyrosine 
phosphorylation of CD8-~, even though comparable amounts 
of chimeric protein were present in anti-CD8 immunopre- 
cipitates from cells cotransfected with the empty vector or 
SH2(N+C)  mutant.  This suggests that the dephosphoryla- 
tion  of CD8-~  was  prevented  by  the  expression  of the 
Figure 8.  Association  of SH2(N+C) mutant and en- 
dogenous ZAP-70 with the CD8-~ chimera. TAgJur- 
kat cells were cotransfected with 5 ~g of CD8-~ ex- 
pression  vector  together  with  40  lxg  of  empty 
expression vector or the  SH2(N+C)  expression plas- 
mid. 40 h later, transfected cens were either left un- 
stimulated or stimulated for 2 rain with anti-CD8 mAb 
OKT8. Cells  were then lysed, and CD8-~ was isolated 
by immunoprecipitation with  mAb OKTS,  followed 
by  immunoblotting  with  anti-ZAP-70  mAb  2F3.2 
(top),  anti-phosphotyrosine  mAb  4G10 (middle),  or 
anti-~ mAb 6B10.2 (bottom). 
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molecule  was  found  to  associate  constitutively  with  the 
CD8-~ chimera at levels that were much greater than en- 
dogenous  ZAP-70.  Anti-CD8  stimulation only induced  a 
slight increase in CD8-~ tyrosine phosphorylation, suggest- 
ing  that  this  phosphorylation  may be  close  to  saturating. 
The basal association of endogenous ZAP-70 with CD8-~ 
was also increased in cells cotransfected with the SH2(N+C) 
mutant. However, this increase in association is not propor- 
tional  to  the  large  increase  in  tyrosine  phosphorylation  of 
CD8-~. These results, combined with a requirement for an 
intact phosphotyrosine-binding site in  the  COOH-termi- 
nal SH2 domain of the SH2(N+C) mutant to demonstrate 
its dominant-negative activity, indicate that the SH2(N+C) 
mutant mediates its effect on TCR signaling by binding to 
tyrosine-phosphorylated TCR subunits. 
Discussion 
In this report, we show that two mutants of the ZAP-70 
PTK functioned  as  dominant-negative  mutants  to  inhibit 
TCR-mediated signal transduction leading to NFAT acti- 
vation. The inhibitory effect of these mutants demonstrated 
remarkable specificity. First,  TCR-mediated transcriptional 
activation of NFAT and NF-IL2A was inhibited (Figs. 2, 3, 
4,  and data not shown), whereas the constitutive activation 
of a reporter construct containing the RSV promoter was 
not inhibited  (data not shown).  Second,  the  inhibition  of 
TCIL-mediated NFAT activation was a dose-dependent ef- 
fect (Fig. 3). Third, only. NFAT activation mediated through 
the  TCR  was  inhibited;  little  or  no  inhibition  was  ob- 
served on NFAT activation induced by PMA plus ionomy- 
cin treatment or by HM1 receptor agonist carbachol stimu- 
lation  (Figs.  2  and  4).  Fourth,  the  inhibition  of NFAT 
activation was due to a block proximal but not distal in the 
TCR signaling pathway (Figs. 2 and 4). These apparent se- 
lectivities strongly argue that a signaling pathway in which 
ZAP-70 is involved was specifically blocked. 
Current models ofT cell activation suggest that ZAP-70 
participates proximally in TCR  signaling, in part, through 
its  interaction  with  tyrosine-phosphorylated  ITAMs  con- 
tained within  the invariant subunits  of the  TCR  complex 
(1, 54). Upon TCR stimulation, the ITAMs become tyro- 
sine phosphorylated, creating high affinity binding sites for 
the  two  SH2  domains  of ZAP-70.  The  recruitment  of 
ZAP-70  from  the  cytosol  to  the  TCR  leads  to  tyrosine 
phosphorylation and activation of ZAP-70. Activated ZAP- 
70 can then act on its targets to elicit subsequent biochem- 
ical responses. The exact mechanism by which ZAP-70 is 
activated has yet to be elucidated.  Nevertheless, it is clear 
that  interfering  with  ZAP-70  function  could have  severe 
consequences for TCR  signaling.  T  cells  from individuals 
lacking ZAP-70  exhibit markedly reduced  or no  tyrosine 
phosphorylation and  calcium influx,  as well as no  detect- 
able  IL-2  production,  upon  TCR.  ligation,  reflecting  an 
early block in  TCR  signaling (13-15).  A  kinase-defective 
ZAP-70 was unable to induce tyrosine phosphorylation of 
cellular proteins in COS cells  (8),  nor could it reconstitute 
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B  cell receptor-mediated activation in B  cell lines lacking 
the homologous Syk PTK (55).  Efforts to inhibit ZAP-70 
binding  to  the  TCR  by introducing  a  phosphatase-resis- 
tant,  tyrosine-phosphorylated  peptide  derived  from  the 
COOH-terminal  ITAM of the  TCR~  chain into  perme- 
abilized T  cells  prevented TC1L-stimulated tyrosine phos- 
phorylation and activation of ZAP-70 and reduced tyrosine 
phosphorylation  of other  substrates  (56).  Unfortunately, 
the  effect of disrupting  ZAP-70 binding  to  the  TCR  on 
late  activation  events,  such  as  IL-2  production,  was  not 
evaluated in this system, probably because of the toxicity of 
permeabilization to the cells. These results collectively sup- 
port the  notion  that the  assembly of a functional  receptor 
signaling  complex  on  the  tyrosine-phosphorylated  TCR 
ITAMs is  an  essential early biochemical event after TCR 
stimulation.  This receptor signaling complex, which  con- 
tains ZAP-70 as a critical component, allows the coupling 
of ligand-binding signal to be transmitted into downstream 
activation. 
Our  biochemical  studies  focused  on  the  SH2(N+C) 
mutant show that  this mutant bound constitutively to the 
tyrosine-phosphorylated CD8-~  chimera (Fig.  8).  In addi- 
tion, the dominant-negative activity of this mutant on both 
early and late TCR signaling requires it to maintain an in- 
tact  phosphotyrosine-binding  site  in  its  COOH-terminal 
SH2  domain  (Figs.  2,  4,  5,  and  6).  These results  indicate 
that the SH2(N+C)  mutant exerts its effect by binding to 
tyrosine-phosphorylated TCR  ITAMs.  This  conclusion is 
also  based on previous studies  demonstrating a  highly re- 
stricted  repertoire  of tyrosine-phosphorylated proteins  to 
which  the  two  SH2 domains  of ZAP-70 bind  (7).  When 
the  two SH2 domains of ZAP-70 were expressed as a fu- 
sion protein and used as an affinity precipitation reagent to 
elute activated T  cell lysates,  only tyrosine-phosphorylated 
TCR~ and CD3e chains were found to bind to the fusion 
protein, in sharp contrast to the binding specificity of other 
SH2  domains.  Binding  of the  SH2(N+C)  mutant  to  ty- 
rosine-phosphorylated CDS-~  chimera correlated with di- 
minished tyrosine phosphorylation of p95  vav (Fig.  6) as well 
as blocks in other signaling events, such as EIt,  K2 activation 
(Fig.  5),  the association of several tyrosine-phosphorylated 
proteins  with  GRB2  (Fig.  7),  and  NFAT induction  (Fig. 
2).  Since  p95  vav becomes  rapidly  tyrosine phosphorylated 
(42,  43) and binds to ZAP-70 (57),  it has been suggested to 
be a downstream substrate for ZAP-70 (57).  Lack of p95  vav 
tyrosine  phosphorylation  implies  that  ZAP-70  activation 
was blocked by the SH2(N+C) mutant. 
The mechanism by which the SH2(N+C) mutant blocks 
ZAP-70 activation is not fully understood. Examination of 
the association of endogenous ZAP-70 with tyrosine-phos- 
phorylated CD8-~ chimera yielded unexpected results (Fig. 
8). Expression of the SH2(N+C) mutant did not appear to 
completely block the association of the endogenous ZAP- 
70 with tyrosine-phosphorylated CD8-~. There are several 
possibilities that  might account for these results.  It should 
be  noted  that  the  association  of ZAP-70  with  tyrosine- 
phosphorylated  TCR  ITAMs  does  not  always  correlate 
with  the  activation  of ZAP-70.  In freshly isolated lymph node T  cells and thymocytes, ZAP-70 constitutively asso- 
ciates with tyrosine-phosphorylated TCR~ chain, yet there 
is no activation (37).  TCR  stimulation is required for the 
increase  in  tyrosine  phosphorylation  of ZAP-70  and  for 
cellular  activation  (37).  In  antagonist-induced  anergic  T 
cells,  ZAP-70  associated  with  one  isoform  of tyrosine- 
phosphorylated  TCR~  chain  but  was  neither  tyrosine 
phosphorylated nor activated upon antagonist peptide stim- 
ulation  (58).  One  model  proposed  by Neumeister  et  al. 
(12)  suggests that an oligomeric complex involving multi- 
ple ZAP-70 molecules aligned tandemly on tyrosine-phos- 
phorylated ITAMs may be a prerequisite for the transphos- 
phorylation and activation of ZAP-70.  Thus, it is possible 
that the SH2(N+C)  mutant might interfere with the tan- 
dem  alignment  of the  endogenous  ZAP-70  on  ITAMs, 
thereby  preventing  the  proper  transphosphorylation  and 
activation. Consistent with this, we observed a reduction in 
the  tyrosine phosphorylation of endogenous  ZAP-70  that 
was associated with the CD8-{ chimera (data not shown). 
Alternatively,  the  presence  of the  SH2(N+C)  mutant  in 
the  same  receptor  complex  could  lock  the  endogenous 
ZAP-70 in an inactive conformation through an intermo- 
lecular  interaction.  Additional  studies  will  be  needed  for 
evidence of an inter- or intramolecular interaction between 
the SH2 domains and the kinase domain of ZAP-70. Such 
interactions  could  normally  serve  as  a  means  of keeping 
ZAP-70  inactive  before  TCR  stimulation.  Upon  ITAM 
engagement, the interaction between the SH2 domains and 
the kinase domain of ZAP-70 may be released to give rise 
to an active conformation. Indeed, a recent study (59) sug- 
gested such a model with the related Syk PTK. In our stud- 
ies,  the SH2(N+C)  mutant was present in great excess, so 
that  the  equilibrium  may  have  been  shifted  toward  the 
maintenance  of an  inactive  conformation.  Future  experi- 
ments are needed to distinguish between these possibilities. 
Although we favor the interpretation that the SH2(N + C) 
mutant inhibited TCR signaling primarily by blocking the 
function  of ZAP-70,  this interpretation  is complicated by 
the possibility that the function of other SH2 domain-con- 
taining  effector  molecules  capable  of binding  to  the  ty- 
rosine-phosphorylated TCR  ITAMs could also  be affected 
by the SH2(N+C) mutant. For example, both Syk and the 
adapter  protein  Shc  can  bind  to  tyrosine-phosphorylated 
TCR{  chain  (60,  61).  However,  a  critical  role  similar to 
that  of ZAP-70  in  TCR  signaling has yet to be  demon- 
strated for Syk or Shc. Thus, the action of SH2(N+C) mu- 
tant may have been to bind tyrosine-phosphorylated ITAMs, 
thereby interfering with the assembly on ITAMs of a func- 
tional receptor signaling complex containing ZAP-70, and 
possibly Syk and Shc. 
The ability of using dominant-negative ZAP-70 mutants 
to  specifically suppress TCR-mediated signal transduction 
leading to functional T  cell activation holds great promise 
for future use of this approach to dissect signaling pathways 
in  which  Syk  family  kinases  are  involved.  It  should  be 
pointed  out  that whereas  ZAP-70  has been shown  to be 
involved primarily in TCR signaling,  Syk has been impli- 
cated in the signaling pathways of a variety of receptors, in- 
cluding the antigen receptors (TCR, B cell antigen receptor 
[BCR],  FceR1,  FcyRl,  and  FcyRII),  cytokine  receptors 
(G-CSFR  and  IL-2R),  and the  erythrocyte thrombin  re- 
ceptor (60,  62-67).  Our prelinfinary results show that the 
two dominant-negative ZAP-70 mutants used in this study 
were also capable of inhibiting BCR-mediated signal trans- 
duction in a B cell line expressing Syk as the only Syk fam- 
ily PTK.  In addition,  Hirasawa et al.  (68)  recently used a 
kinase  domain-truncated  Syk  mutant  to  block  FceR1- 
mediated signaling in mast cells. Without doubt, the domi- 
nant-negative approach, combined with other genetic and 
biochemical approaches, should yield a better understand- 
ing of the molecular mechanisms that regulate the activation 
signals transduced by these receptors. 
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